

NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES

DESPATCH OF RETAIL OFFER DOCUMENT

PERTH, Australia – 20 March 2024

PYC Therapeutics Limited (ASX:PYC) advises that it has today despatched the Retail Offer Booklet relating to the accelerated non-renounceable entitlement offer announced on 14 March 2024. A copy of the Retail Offer Booklet was released to the ASX today.

Commencement of the Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will open today and will close at 5.00pm (AWST) Monday, 8 April 2024 (unless varied).

Eligible shareholders on the record date of 4.00pm (AWST) on Monday, 18 March 2024, may participate in the Retail Entitlement Offer at the issue price of \$0.08 per new share, on the basis of 1 new share for every 4 existing shares held.

Retail Investor Enquiries

If you have any queries concerning the Retail Entitlement Offer, or the action you are required to take to subscribe for new shares, please consult your stockbroker, accountant, solicitor or other professional advisor. For Further information about the Retail Entitlement Offer you can call Automic Share Registry on 1300 228 664 (within Australia) or +61 2 8072 1400 (outside Australia) from 8.30am to 6.00pm (Sydney time) Monday to Friday during the Retail Offer Period.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class.

For personal use only

PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. The Company is progressing a second blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and late 2024 respectively.

For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>